

SCIENTIFIC REPORTS



OPEN

Onco-lncRNA *HOTAIR* and its functional genetic variants in papillary thyroid carcinoma

Hui Zhu^{1,*}, Zheng Lv^{2,*}, Changming An³, Meng Shi⁴, Wenting Pan⁴, Liqing Zhou⁵, Wenjun Yang⁶ & Ming Yang⁷

Received: 11 May 2016

Accepted: 01 August 2016

Published: 23 August 2016

The role of long noncoding RNA (lncRNA) HOX transcript antisense RNA (*HOTAIR*) and its functional single nucleotide polymorphisms (SNPs) in papillary thyroid carcinoma (PTC) is still largely unclear. Therefore, we investigated the involvement of lncRNA *HOTAIR* and its three haplotype-tagging SNPs (htSNPs) in PTC. There was higher expression of *HOTAIR* in PTC tissues compared to normal tissues. A series of gain-loss assays demonstrated that *HOTAIR* acts as a PTC oncogene via promoting tumorigenic properties of PTC cells. Additionally, the functional *HOTAIR* rs920778 genetic variant was a PTC susceptibility SNP. Subjects with the *HOTAIR* rs920778 TT genotype had an odds ratio (OR) of 1.88, 1.25 and 1.61 ($P = 6.0 \times 10^{-6}$, $P = 0.028$ and $P = 3.2 \times 10^{-5}$) for developing PTC in Shandong, Jiangsu and Jilin case-control sets compared with subjects with the CC genotype. This statistically significant associations were only found between the rs920778 genetic polymorphism and PTC risk in females but not in males. The allele-specific regulation on *HOTAIR* expression by the rs920778 SNP was confirmed both *in vitro* and *in vivo*. Our results demonstrate that functional SNPs influencing lncRNA regulation may explain a part of PTC genetic basis.

As the most common endocrine malignancy, thyroid carcinoma showed quickly increased morbidity over last two decades. The Chinese Cancer Registry reported that the incidence of thyroid carcinoma is 6.6 per 100,000 individuals in China¹. Among all patients with thyroid carcinoma, about eighty percents carried papillary thyroid carcinoma (PTC) which was named for its papillary histological architecture. Multiple risk factors of PTC have been identified, such as ionizing radiation, nodular disease of the thyroid and family history². However, not all exposed individuals finally developed PTC, indicating that genetic makeup may also be involved in etiology of PTC³. New insights into the pathogenesis of this malignant disease are therefore needed.

Long noncoding RNAs (lncRNAs) comprise a very heterogeneous subclass of RNAs that were firstly described by the genome-wide sequencing of cDNA libraries of the mouse genome⁴. It is becoming clear that a large number of lncRNAs are key regulators of physiology and the processes of diseases such as cancers, despite so often being branded as transcriptional noise⁴. LncRNA HOX transcript antisense RNA (*HOTAIR*) is coded from the homeobox C gene (*HOXC*) locus and involved in development and progression of multiple malignances⁴⁻¹¹. As one of the trans-regulatory lncRNAs, *HOTAIR* facilitates aberrant PRC2 function by increasing PRC2 recruitment to the genomic positions of target genes and, thus, promotes malignant transformation and cancer cell metastasis⁴⁻¹¹. In line with this, *HOTAIR* is upregulated in cancer tissues and overexpression of *HOTAIR* might be an independent predictor of overall survival and progression-free survival^{4,5}. All these reports elucidate the involvement of *HOTAIR* during carcinogenesis. However, it is still largely unclear how *HOTAIR* is involved in

¹Department of Radiation Oncology, Shandong Cancer Hospital affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong Province, China. ²Cancer Center, The First Affiliated Hospital of Jilin University, Changchun, Jilin Province, China. ³Department of Head and Neck Surgical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China. ⁴College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China. ⁵Department of Radiation Oncology, Huaian No. 2 Hospital, Huaian, Jiangsu Province, China. ⁶Key Laboratory of Fertility Preservation and Maintenance (Ministry of Education), Ningxia Medical University, Yinchuan, Ningxia, China. ⁷Shandong Provincial Key Laboratory of Radiation Oncology, Cancer Research Center, Shandong Cancer Hospital affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong Province, China. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to M.Y. (email: aaryoung@yeah.net)

malignant transformation of thyroid cells. Therefore, we examined its expression in tissue specimens of PTC and normal thyroid tissues and elucidated its oncogene nature in PTC cells.

In two previous studies, we reported the functional significance of the lncRNA *HOTAIR* single nucleotide polymorphisms (SNP) in esophageal squamous cell carcinoma (ESCC) and gastric cancer^{12,13}. We found that the *HOTAIR* rs920778 TT genotype was significantly associated with increased risk of ESCC and gastric cancer^{12,13}. During inspecting functional relevance of the rs920778 SNP, we identified a novel intronic *HOTAIR* enhancer locating between +1719 bp and +2353 bp from the transcriptional start site through dual luciferase reporter gene assays. Moreover, there is an allelic regulation of rs920778 on lncRNA *HOTAIR* expression via this enhancer in both ESCC and gastric cancer, with higher *HOTAIR* expression among T allele carriers. To date, little or nothing has been known on how *HOTAIR* SNPs are involved in etiology of PTC. On the basis of our previous findings, we hypothesized that the functional genetic variants in the *HOTAIR* gene may affect *HOTAIR* expression and influence consequential risk of developing PTC. To test this hypothesis, we genotyped three *HOTAIR* haplotype-tagging SNPs (htSNP) in three large independent case-control sets to examine the association between *HOTAIR* genotypes and PTC risk. The regulatory functions of the PTC susceptibility SNP rs920778 on *HOTAIR* expression was then investigated in PTC cell lines and in patient tissue specimens.

Materials and Methods

Real-time analyses of lncRNA *HOTAIR*. Total cellular RNA was isolated from culture cells, sixty pairs of PTC tissues and normal specimens adjacent to the tumors with TRIzol Reagent (Invitrogen, US) and treated with RNase-Free DNase to remove genomic DNA (Invitrogen). Each RNA sample was reverse transcribed into cDNA with Revert Ace kit (TOYOBO, Osaka, Japan). Relative gene expression of lncRNA *HOTAIR* in tissues was analyzed using the SYBR-Green real-time quantitative PCR method. The expression of *HOTAIR* of individual specimen was calculated relative to expression of β -actin mRNA using the $2^{-\Delta\Delta Ct}$ method as described previously¹²⁻¹⁵. All qPCR was carried out using the ABI 7500 real-time PCR system in triplicates.

Cell proliferation assays. Human PTC BCPAP or HEK293 cells were cultured in RPMI 1640 medium (Invitrogen) supplemented with penicillin-streptomycin and 10% fetal bovine serum (Hyclone, US) at 37 °C with 5% CO₂. Cells were seeded in a 12-well plate at a density of 10⁵ cells per well. BCPAP or HEK293 cells were transfected with the *HOTAIR* expression construct or pcDNA3.1 vector with Lipofectamine 2000 (Invitrogen). In the gene silencing assays, different concentrations of negative control RNA (NC) or *HOTAIR* siRNAs (siH-1 and siH-2) (Genepharma, China) were transfected into BCPAP cells combined with Lipofectamine RNAi Max (Invitrogen). Cells were then harvested by trypsin digestion, washed by cold PBS twice, dyed with trypan blue and counted under microscopy at 24 h, 48 h and 72 h after transfection.

Colony formation assays. A total of 5000 BCPAP or HEK293 cells per well were seeded into a 6-well cell culture plate and transfected with the *HOTAIR* expression construct or pcDNA3.1 vector. After 13 days, cells were washed with cold PBS twice and fixed with 3.7% formaldehyde.

Study case-control sets. This study consisted of three case-control sets: (a) Shandong set: 600 patients with PTC Shandong Cancer Hospital (Jinan, Shandong Province, China) and sex- and age-matched (± 5 years) 600 controls. (ii) Jiangsu set: 1000 cases with PTC from Huaian No. 2 Hospital (Huaian, Jiangsu Province, China) and sex- and age-matched (± 5 years) 1000 healthy controls. (iii) Jilin set: 800 PTC patients from The First Affiliated Hospital of Jilin University (Changchun, Jilin Province, China) and 800 sex- and age-matched healthy controls. Sixty pairs of PTC specimens and thyroid normal tissues adjacent to the tumors were obtained from surgically removed specimens of patients in Shandong Cancer Hospital and Huaian No. 2 Hospital. All individuals were ethnic Han Chinese. The detailed information on characteristics of PTC cases and controls can be found in Supplementary Table 1. This study was approved by the institutional Review Boards of Shandong Cancer Hospital, Huaian No. 2 Hospital and The First Affiliated Hospital of Jilin University. At recruitment, the written informed consent was obtained from each subject. The methods were carried out in accordance with the relevant guidelines.

***HOTAIR* SNP genotyping.** Three *HOTAIR* htSNPs (rs920778, rs1899663, and rs4759314) were selected and genotyped as described previously^{12,13}. SNP genotyping was performed without knowledge of patient or control status. A 15% random sample was reciprocally tested by different individuals, and the reproducibility was 99.7%.

Dual luciferase reporter assay. The intron 2 region of *HOTAIR* (from +1463 bp to +2353 bp, relative to the transcription start site) was amplified with human genomic DNA from healthy controls to build intronic enhancer reporter constructs as described previously^{12,13}. The p-C construct (the rs920778C allele) and p-T (the rs920778T allele) constructs were identical, except for the different allele at the rs920778 polymorphic site. The reporter gene constructs pGL3-Basic, p-C, or p-T as well as pRL-SV40 (Luciferase Assay System; Promega) were co-transfected into PTC cell line BCPAP cells or HEK293 cells. Both firefly luciferase activity and renilla luciferase activity were measured at 48 h after transfection using a dual luciferase assay system (Promega) as previously described¹²⁻¹⁵. For each plasmid construct, three independent transfection experiments were performed, and each was done in triplicates.

Statistics. Pearson's χ^2 test was used to examine the differences in demographic variables and genotype distributions of *HOTAIR* htSNPs between PTC cases and controls. Associations between *HOTAIR* genotypes and PTC risk were estimated by odds ratio (OR) and their 95% confidence intervals (CIs) computed using the unconditional logistic regression model. All ORs were adjusted for age and sex, where it was appropriate. A *P* value of




Figure 1. *HOTAIR* acts as an oncogene in PTC. (A) *HOTAIR* RNA expression detected in 60 pairs of PTC tissue specimens and normal tissues. (B) Ectopically expressed *HOTAIR* could significantly stimulate cell viability in BCPAP cells. (C) Depletion of *HOTAIR* expression in BCPAP cells significantly inhibited cell proliferation. (D) Over-expression of lncRNA *HOTAIR* could significantly promote cell growth of HEK293 cells. (E) Colony formation assays. At the 13rd day after transfection of the *HOTAIR* expression construct or pcDNA3.1 vector, cells were washed with cold PBS twice and fixed with 3.7% formaldehyde. All experiments were performed in triplicates in three independent transfection experiments and each value represents mean \pm SD. ** $P < 0.01$.

less than 0.05 was used as the criterion of statistical significance. All statistical tests were two-sided and performed with the SPSS software package (Version 16.0, SPSS Inc., Chicago, IL).

Results

By detecting *HOTAIR* RNA expression in sixty paired PTC and normal tissues, we found higher expression of *HOTAIR* in PTC tissues compared to normal tissues ($P < 0.05$) (Fig. 1A). In BCPAP or HEK293 cells, ectopic expression of lncRNA *HOTAIR* significantly promoted cell proliferation (Fig. 1B,C). On the contrary, depletion of endogenous *HOTAIR* expression significantly suppresses PTC cell proliferation (Fig. 1D). In line with cell viability assays, *HOTAIR* is able to promote colony formation in both BCPAP and HEK293 cells (Fig. 1E). These results are consistent to the role of *HOTAIR* in other malignancies, indicating the oncogene nature of *HOTAIR* in PTC development.

Considering the important involvement of genetic polymorphisms in regulating expression of *HOTAIR*, we next investigated the association between three *HOTAIR* htSNPs (rs920778 C>T, rs1899663 G>T, and rs4759314 A>G) and PTC susceptibility in a case-control design. A total of three case-control sets were included in the current study. There are no statistically significant differences between PTC cases and controls for all three sets in terms of median age and sex distributions (all $P > 0.05$), indicating that the frequency matching was adequate (Supplementary Table 1). Allele frequencies and genotype distributions of *HOTAIR* htSNPs in cases and controls from the Shandong training set are showed in Table 1. The allele frequencies for rs920778 T, rs1899663 T and

#	Identity	Location	Position ¹	Case	Common genotype %	Heterozygous genotype %	Rare genotype %	OR ² (95% CI) for heterozygote	P	OR ² (95% CI) for rare genotype	P
1	rs920778 (C>T)	Intron 2	52646499	PTC	288(48.0)	259(43.2)	53(8.8)	1.60(1.26–2.03)	1.2 × 10 ⁻⁴	1.88(1.43–2.47)	6.0 × 10 ⁻⁶
				Control	372(62.0)	209(34.8)	19(3.2)				
2	rs1899663 (G>T)	Intron 2	52647261	PTC	442(73.6)	151(25.2)	7(1.2)	0.81(0.63–1.04)	0.103	0.72(0.45–1.15)	0.716
				Control	413(68.8)	175(29.2)	12(2.0)				
3	rs4759314 (A>G)	Intron 1	52648102	PTC	540(90.0)	58(9.7)	2(0.3)	1.34(0.99–2.01)	0.163	1.01(0.38–2.70)	0.986
				Control	553(92.2)	45(7.5)	2(0.3)				

Table 1. Associations between candidate SNPs in *HOTAIR* and PTC risk in Shandong case-control set (Training set). Note: PTC, papillary thyroid carcinoma; OR, odds ratio; CI, confidence interval. ¹Position in NCBI build 36. ²Data were calculated by unconditional logistic regression, adjusted of age and sex.

Studies	Genotypes	Cases No. (%)	Controls No. (%)	OR ¹ (95% CI)	P ¹
Shandong set		n = 600	n = 600		
	CC	288(48.0)	372(62.0)	1.00 (Reference)	
	CT	259(43.2)	209(34.8)	1.60(1.26–2.03)	1.2 × 10 ⁻⁴
	TT	53(8.8)	19(3.2)	1.88(1.43–2.47)	6.0 × 10 ⁻⁶
Jiangsu set		n = 1000	n = 1000		
	CC	553(55.3)	608(60.8)	1.00 (Reference)	
	CT	385(38.5)	348(34.8)	1.22(1.01–1.47)	0.038
	TT	62(6.2)	44(4.4)	1.25(1.02–1.53)	0.028
Jilin set		n = 800	n = 800		
	CC	416(52.0)	485(60.6)	1.00 (Reference)	
	CT	316(39.5)	284(35.5)	1.30(1.06–1.60)	0.014
	TT	68(8.5)	31(3.9)	1.61(1.28–2.01)	3.2 × 10 ⁻⁵
Pooled		n = 2400	n = 2400		
	CC	1257(52.4)	1465(61.0)	1.00 (Reference)	
	CT	960(40.0)	841(35.0)	1.40(1.21–1.63)	7.8 × 10 ⁻⁶
	TT	183(7.6)	94(4.0)	1.66(1.41–1.95)	8.1 × 10 ⁻¹⁰

Table 2. Genotype frequencies of the *HOTAIR* rs920778 C>T polymorphism among PTC cases and controls and their association with PTC risk. Note: PTC, papillary thyroid carcinoma; OR, odds ratio; CI, confidence interval. ¹Data were calculated by logistic regression with adjustment for age and sex.

rs4759314 G were 0.304, 0.138, and 0.052 in cases and 0.206, 0.166, and 0.041 in controls in Shandong training case-control set. All observed genotype frequencies in both cases and controls conform to Hardy-Weinberg equilibrium. Distributions of the rs920778, rs1899663 and rs4759314 genotypes were compared between cases and controls. Frequencies of rs920778 CC, CT, and TT genotypes among PTC cases differed significantly from those among controls ($\chi^2 = 30.68$, $P = 3.0 \times 10^{-8}$, $df = 2$), with the frequency of TT homozygote being significantly higher among patients than among controls (8.8% vs. 3.2%). However, no statistically significant differences of rs1899663 and rs4759314 genotypes were observed between cases and controls (both $P > 0.05$). As a result, we did not do further investigations on these two genetic polymorphisms.

Associations between genotypes of *HOTAIR* rs920778 and PTC risk were firstly estimated in Shandong training set (Table 2). The rs920778 T allele was shown to be risk allele. Subjects with the rs920778 TT genotype had an OR of 1.88 (95% CI = 1.43–2.47, $P = 6.0 \times 10^{-6}$) for developing PTC in Shandong population compared with subjects with the CC genotype. This association was successfully validated in the other two independent case-control sets (Jiangsu set: OR = 1.25, 95% CI = 1.02–1.53, $P = 0.028$; Jilin set: OR = 1.61, 95% CI = 1.28–2.01, $P = 3.2 \times 10^{-5}$) (Table 2). Interestingly, the rs920778 CT genotype was also significantly associated with increased PTC risk compared to the rs920778 CC genotype in all three sets (Shandong: OR = 1.60, 95% CI = 1.26–2.03, $P = 1.2 \times 10^{-4}$; Jiangsu: OR = 1.22, 95% CI = 1.01–1.47, $P = 0.038$; Jilin: OR = 1.30, 95% CI = 1.06–1.60, $P = 0.014$). In the pooled analyses, the rs920778 CT or TT genotype carriers showed a 1.40-fold or 1.66-fold increased PTC risk compared with the CC genotype carriers (95% CI = 1.21–1.63, $P = 7.8 \times 10^{-6}$ or, 95% CI = 1.41–1.95, $P = 8.1 \times 10^{-10}$) (Table 2). The PTC risk associated with the rs920778 genetic variant was further examined by stratifying for age and sex using the combined data of three case-control sets (Table 3). Statistically significant associations were found between the rs920778 genetic polymorphism and PTC risk only in females but not in males, with OR of CT genotype or TT genotype equaling to 1.46 (95% CI = 1.22–1.73, $P = 2.1 \times 10^{-5}$) or 1.75 (95% CI = 1.45–2.10, $P = 2.4 \times 10^{-9}$). Significant associations between rs920778 CT or TT genotype and PTC risk were observed in all age-stratified groups (all $P < 0.05$) (Table 3).

Our previous studies demonstrated that the PTC susceptibility SNP rs920778 is a functional genetic variant located within a potential *HOTAIR* enhancer^{12,13}. Therefore, we investigated its regulatory potential in PTC using

Variable	rs920778 C>T						
	CC ¹	CT ¹	OR ² (95% CI)	P	TT ¹	OR ² (95% CI)	P
Sex							
Male	300/388	271/230	1.26(0.95–1.69)	0.114	35/25	1.37(0.97–1.94)	0.074
Female	957/1077	689/611	1.46(1.22–1.73)	2.1×10^{-5}	148/69	1.75(1.45–2.10)	2.4×10^{-9}
Age (year)							
≤47	620/722	471/448	1.24(1.01–1.53)	0.045	99/45	1.59(1.29–1.96)	1.6×10^{-5}
>47	637/743	489/393	1.88(1.49–2.37)	1.0×10^{-7}	84/49	1.46(1.16–1.83)	0.001

Table 3. Risk of PTC associated with *HOTAIR* rs920778 C>T genotypes by age and sex. Note: PTC, papillary thyroid carcinoma; OR, odds ratio; CI, confidence interval. ¹Number of case patients with genotype/number of control subjects with genotype. ²Data were calculated by logistic regression, adjusted for sex and age, where it was appropriate.




Figure 2. Transient luciferase reporter gene assays with constructs containing different rs920778 allele of *HOTAIR* in BCPAP cells (A) or 293T cells (B). pRL-SV40 were cotransfected with these constructs to standardize transfection efficiency. Fold-changes were detected by defining the luciferase activity of cells co-transfected with pGL3-basic as 1. All experiments were performed in triplicates in three independent transfection experiments and each value represents mean \pm SD. Compared with pGL3-Basic transfected cells, * $P < 0.05$; ** $P < 0.01$.

reporter gene assays (Fig. 2). Both BCPAP cells or 293T cells transfected with *HOTAIR* rs920778T allelic reporter construct (p-T) showed significantly elevated luciferase activities compared to cells expressing rs920778C allelic reporter construct (p-C) (both $P < 0.05$) (Fig. 2).

We next examined whether the PTC susceptibility SNP rs920778 has an allele-specific effect on *HOTAIR* expression using PTC tissues. As shown in Fig. 3, we found that subjects with the rs920778 CT or TT genotype had significantly higher *HOTAIR* RNA levels (mean \pm SD) than those with the CC genotypes in normal tissues (CC: 0.0002 ± 0.0001 [$n = 31$], CT: 0.0006 ± 0.0003 [$n = 24$], TT: 0.0008 ± 0.0004 [$n = 5$]; CC vs. CT: $P = 0.045$, CC vs. TT: $P = 0.045$). Similar results were observed when the *HOTAIR* RNA levels were compared between rs920778 CT or TT and CC genotypes in PTC tissues (CC: 0.0009 ± 0.0004 [$n = 31$], CT: 0.0016 ± 0.0006 [$n = 24$], TT: 0.0025 ± 0.0012 [$n = 5$]; CC vs. CT: $P = 0.005$, CC vs. TT: $P = 0.009$).

Discussion

In the current study, we investigated the oncogene role of lncRNA *HOTAIR* in PTC and the association between *HOTAIR* htSNPs and PTC risk through a two stage case-control approach. To the best of our knowledge, this is the first study to examine how lncRNA *HOTAIR* and its genetic polymorphisms play their role in PTC development. We found that the functional *HOTAIR* rs920778 SNP was a PTC susceptibility polymorphism in Chinese. Dual luciferase reporter gene assays and tissue data indicated that the rs920778 SNP in the gene enhancer impacts lncRNA *HOTAIR* expression in an allele-specific way, which is consistent to our previous findings in gastric cancer and esophageal cancer^{12,13}.

We and others have identified multiple lncRNAs involved in PTC tumorigenesis and progression. Yoon H *et al.* identified a novel noncoding RNA gene, NAMA (noncoding RNA associated with MAP kinase pathway and growth arrest), that is downregulated in PTC with BRAF mutation and associated with growth arrest¹⁶. Jendrzejewski J *et al.* described a unique lncRNA named Papillary Thyroid Carcinoma Susceptibility Candidate 3 (PTCSC3) located 3.2 kb downstream of rs944289 at 14q.13.3 which is a GWAS identified PTC susceptibility region¹⁷. lncRNA PTCSC3 is involved in PTC development by modulating S100A4 gene expression¹⁸. Interestingly, a novel lncRNA papillary thyroid cancer susceptibility candidate 2 (PTCSC2) gene was found locating in another 9q22 PTC risk loci¹⁹. We performed a whole exome sequencing in 91 pairs PTC samples and identified a lncRNA GAS8-AS1 as novel PTC driver alternations²⁰. In addition, several other lncRNAs including FAL1, LOC100507661, H19, ENST00000537266 and ENST00000426615 are involved in PTC development^{21–24}.




Figure 3. *HOTAIR* RNA expression in normal thyroid tissue specimens and PTC tissues grouped by rs920778 genotypes. The expression of individual *HOTAIR* RNA was calculated relative to expression of β -actin mRNA using the 2^{-dCt} method. * $P < 0.05$; ** $P < 0.01$.

However, it is still largely unknown if onco-lncRNA *HOTAIR* also plays a part in PTC. We found that elevated *HOTAIR* can promote PTC cell proliferation and silencing its expression inhibits cell growth, suggesting its oncogene nature in PTC. Our results demonstrated that *HOTAIR* rs920778T allele is a PTC risk allele and is associated with significantly increased *HOTAIR* RNA expression. Considering the oncogene role of *HOTAIR* in PTC, the association might be biological rational.

Multiple limitations exist in our hospital-based case-control study. For example, the hospital-based design might lead to inherent selection bias of PTC cases. Therefore, the results of our current study warrant to be validated in a population-based prospective study in the future. Moreover, the potential clinical translation of this SNP might be compromised due to the relatively low allele frequency of the rs920778 TT genotype.

In summary, we identified the involvement of lncRNA *HOTAIR* in PTC development and a functional PTC susceptibility SNP rs920778 in Chinese Han populations. The rs920778 C>T polymorphism leads to increased *HOTAIR* RNA expression, which might be the underlying mechanism in conferring PTC susceptibility. These data support the hypothesis that functional SNPs influencing lncRNA regulation may explain a part of PTC genetic basis^{17–19}.

References

- Chen, W. *et al.* Annual report on status of cancer in China, 2011. *Chin J Cancer Res* **27**, 2–12 (2015).
- Schneider, A. B. & Sarne, D. H. Long-term risks for thyroid cancer and other neoplasms after exposure to radiation. *Nat Clin Pract Endocrinol Metab* **1**, 82–91 (2005).
- Goldgar, D. E., Easton, D. F., Cannon-Albright, L. A. & Skolnick, M. H. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. *J Natl Cancer Inst* **86**, 1600–1608 (1994).
- Liz, J. & Esteller, M. lncRNAs and microRNAs with a role in cancer development. *Biochim Biophys Acta* **1859**, 169–176 (2016).
- Gupta, R. A. *et al.* Long non-coding RNA *HOTAIR* reprograms chromatin state to promote cancer metastasis. *Nature* **464**, 1071–1076 (2010).
- Kogo, R. *et al.* Long noncoding RNA *HOTAIR* regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. *Cancer Res* **71**, 6320–6326 (2011).
- Niinumata, T. *et al.* Upregulation of miR-196a and *HOTAIR* drive malignant character in gastrointestinal stromal tumors. *Cancer Res* **72**, 1126–1136 (2012).
- Kim, K. *et al.* *HOTAIR* is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. *Oncogene* **32**, 1616–1625 (2013).
- Li, Y. *et al.* HBXIP and LSD1 Scaffolded by lncRNA *Hotair* Mediate Transcriptional Activation by c-Myc. *Cancer Res* **76**, 293–304 (2016).
- Zhang, A. *et al.* lncRNA *HOTAIR* Enhances the Androgen-Receptor-Mediated Transcriptional Program and Drives Castration-Resistant Prostate Cancer. *Cell Rep* **13**, 209–221 (2015).
- Pastori, C. *et al.* The Bromodomain protein BRD4 controls *HOTAIR*, a long noncoding RNA essential for glioblastoma proliferation. *Proc Natl Acad Sci USA* **112**, 8326–8331 (2015).
- Zhang, X. *et al.* The identification of an ESCC susceptibility SNP rs920778 that regulates the expression of lncRNA *HOTAIR* via a novel intronic enhancer. *Carcinogenesis* **35**, 2062–2067 (2014).
- Pan, W. *et al.* A functional lncRNA *HOTAIR* genetic variant contributes to gastric cancer susceptibility. *Mol Carcinog* **55**, 90–96 (2016).
- Ge, Y. *et al.* fMiRNA-192 and miRNA-204 Directly Suppress lncRNA *HOTTIP* and Interrupt GLS1-Mediated Glutaminolysis in Hepatocellular Carcinoma. *PLoS Genet* **11**, e1005726 (2015).
- Wang, X. *et al.* Silencing of long noncoding RNA *MALAT1* by miR-101 and miR-217 inhibits proliferation, migration, and invasion of esophageal squamous cell carcinoma cells. *J Biol Chem* **290**, 3925–3935 (2015).

16. Yoon, H. *et al.* Identification of a novel noncoding RNA gene, NAMA, that is downregulated in papillary thyroid carcinoma with BRAF mutation and associated with growth arrest. *Int J Cancer* **121**, 767–775 (2007).
17. Jendrzewski, J. *et al.* The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type. *Proc Natl Acad Sci USA* **109**, 8646–8651 (2012).
18. Jendrzewski, J. *et al.* PTCSC3 Is Involved in Papillary Thyroid Carcinoma Development by Modulating S100A4 Gene Expression. *J Clin Endocrinol Metab* **100**, E1370–1377 (2015).
19. He, H. *et al.* Genetic predisposition to papillary thyroid carcinoma: involvement of FOXE1, TSHR, and a novel lincRNA gene, PTCSC2. *J Clin Endocrinol Metab* **100**, E164–172 (2015).
20. Pan, W. *et al.* Whole exome sequencing identifies lincRNA GAS8-AS1 and LPAR4 as novel papillary thyroid carcinoma driver alternations. *Hum Mol Genet* **25**, 1875–1884 (2016).
21. Jeong, S. *et al.* Relationship of Focally Amplified Long Noncoding on Chromosome 1 (FAL1) lincRNA with E2F Transcription Factors in Thyroid Cancer. *Medicine (Baltimore)* **95**, e2592 (2016).
22. Liu, L. *et al.* Long noncoding RNA H19 competitively binds miR-17-5p to regulate YES1 expression in thyroid cancer. *FEBS J* **283**, 2326–2339 (2016).
23. Kim, D. *et al.* Upregulation of long noncoding RNA LOC100507661 promotes tumor aggressiveness in thyroid cancer. *Mol Cell Endocrinol* **S0303–7207**, 30150–30152 (2016).
24. Xu, B. *et al.* The Long Non-Coding RNA ENST00000537266 and ENST00000426615 Influence Papillary Thyroid Cancer Cell Proliferation and Motility. *Cell Physiol Biochem* **38**, 368–378 (2016).

Acknowledgements

This study was financially supported by the National High-Tech Research and Development Program of China (2015AA020950); National Natural Science Foundation of China (31271382, 81502291); Natural Science Foundation of Shandong Province (ZR2015HM040).

Author Contributions

M.Y. and H.Z. conceived and designed the experiments; H.Z. and Z.L. performed the experiments; H.Z. analyzed the data; Z.L., M.S., W.P., L.Z., C.A. and W.Y. contributed materials/analysis tools; M.Y. and Z.L. wrote the manuscript. All authors reviewed and approved the manuscript prior to submission.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Zhu, H. *et al.* Onco-lincRNA *HOTAIR* and its functional genetic variants in papillary thyroid carcinoma. *Sci. Rep.* **6**, 31969; doi: 10.1038/srep31969 (2016).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2016